Joaquin Mateo
Joaquin Mateo, MD, PhD
Joaquin Mateo is Group Leader of the Prostate Cancer Research Group at Vall d’Hebron Institute of Oncology (VHIO) and a Medical Oncologist at Vall d’Hebron University Hospital in Barcelona, Spain. His research focuses on prostate cancer genomics and precision oncology, with key contributions to PARP inhibitor development and biomarker discovery.
Disclosures: Advisor for AstraZeneca, Amunix/Sanofi, Daiichi-Sankyo, Janssen, MSD, Pfizer, and Roche. Scientific board member for Nuage Therapeutics. Investigator in several pharma-sponsored clinical trials. Principal investigator of grants funded by Amgen, AstraZeneca, and Pfizer to VHIO.
View content featuring Mateo:
This content has been developed independently by Medthority who previously received educational funding from Pfizer in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.
of interest
are looking at
saved
next event